Pharmacogenomics in Cardiovascular disease
Introduction:
Pharmacogenomics integrates genetics and pharmacology to individualize drug therapy, ensuring the right drug at the right dose for each patient. In cardiovascular diseases, genetic markers help predict drug response, metabolism, and toxicity. Studies indicate that pharmacogenomics is clinically significant for about 72% of cardiovascular medications, underscoring its essential role in cardiac care.
Pharmacogenomics guidance for key cardiac drugs
Genetic testing for specific genes helps clinicians tailor drug selection and dosage for critical cardiovascular medications:
| Drug class | Example | Key genes | Impact of variation | Guidance for Personalized treatment |
|---|---|---|---|---|
| Anticoagulants (Strong evidence) | Warfarin | CYP2C9, VKORC1 | Variations affect drug metabolism & sensitivity | Dose adjustment to avoid bleeding/subtherapeutic effect. |
| Anti-platelet Agents (Strong evidence) | Clopidogrel | CYP2C19 | poor metabolizers - fail to activate | Prasugrel or Ticagrelor in poor metabolizers. |
| Lipid-Lowering (Moderate) | Statins | SLCO1B1 | Increased risk of myopathy | Dose/choice adjustment to avoid myopathy |
| Blood pressure (Limited evidence) | ACE Inhibitors | ADTR1 | Variants affect response and outcomes | Helps identify patients with poor response to ACE inhibitor therapy. |
| Rhythm control (Minimal evidence) | Beta-Blockers | CYP2D6 | Alters metabolism & receptor response | Adjust to improve heart rate control & reduce adverse effects |
Impact on recent times & future trends
Genotype-guided therapy has moved from research into mainstream cardiology practice. Integration with clinical decision-support tools enables personalized prescribing, especially for anticoagulants, antiplatelet agents, and statins. Rapid genotyping, next-generation sequencing, and multi-omics analysis now facilitate faster and more accurate testing. Emerging tools include:
- CRISPR-based editing for correcting pathological gene variants.
- AI-driven analytics for interpreting complex genetic data in real time.
- Wearable biosensors that monitor therapy response dynamically.
These innovations collectively enhance individualized cardiovascular care and therapeutic precision.
